Two ICU morning meetings (Academic Year 2007-2008) will be devoted a Journal Club on both dates below.
Anesthesia meetings will continue as normal in the afternoon.
![]() |
![]() |
All residents are asked to prepare for presentation either the ADDRESS (+ followup) or PROWESS study group from the list below.
Please review the other articles for active participation in the discussion.
Please inform Dr. Nini which presentation you have chosen to prepare
The articles concerned may be download here in pdf format:
References
Article - Author - Publication Journal - Date
Size - Format
Download
EFFICACY AND SAFETY OF RECOMBINANT HUMAN ACTIVATED PROTEIN C
FOR SEVERE SEPSIS PROWESS STUDY GROUP
GORDON R. BERNARD, M.D., JEAN-LOUIS VINCENT, M.D., PH.D., PIERRE-FRANCOIS LATERRE
et al.
N Engl J Med, Vol. 344, No. 10
Published at www.nejm.org on March 8, 2001 545 KB Adobe***
Drotrecogin Alfa (Activated) for Adults
with Severe Sepsis and a Low Risk of Death ADDRESS PAPER
Edward Abraham, M.D., Pierre-Fran?ois Laterre, M.D., Rekha Garg, M.D.,et al.
N Engl J Med 2005;353:1332-41
Published at www.nejm.org on Sep 29, 2005 140 KB Adobe***
ADDRESS (ADministration of DRotrecogin alfa [activated] in
Early stage Severe Sepsis) long-term follow-up: One-year safety
and efficacy evaluation ADDRESS FOLLOWUP
Pierre-Francois Laterre, MD; Edward Abraham, MD; Jonathan M. Janes, FRCP;
Benjamin L. Trzaskoma, MS; Nancy L. Correll; Frank V. Booth, MD
Crit Care Med 2007 Vol. 35, No. 6
Published at www.nejm.org (2007)
853 KB Adobe***
Recombinant human activated protein C sentenced to the death of a thousand cuts?
EDITORIAL
James M. O’Brien, MD, MSc, Division of Pulmonary, Allergy, Critical Care and Sleep
The Ohio State University Medical Center Columbus, OH
Crit Care Med 2007 Vol. 35, No. 6
Published at www.nejm.org (2007)
84 KB Adobe***
FDA BRIEFING DOCUMENT: ANTI-INFECTIVE ADVISORY COMMITTEE DROTRECOGIN ALFA (ACTIVATED) [RECOMBINANT HUMAN ACTIVATED PROTEIN C (rhAPC)] XIGRIS™
SEPTEMBER 12, 2001
488 KB Adobe***